Feasibility and utility of controlled attenuation parameter and transient elastography in the assessment of nonalcoholic fatty liver disease severity in children

2018 ◽  
Vol 68 ◽  
pp. S577-S578
Author(s):  
A. Scott ◽  
M. Mansouri ◽  
T. Okubote ◽  
M. Scott ◽  
A. Betancourt ◽  
...  
Diagnostics ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 787
Author(s):  
Sebastian Zenovia ◽  
Carol Stanciu ◽  
Catalin Sfarti ◽  
Ana-Maria Singeap ◽  
Camelia Cojocariu ◽  
...  

Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP) is a widely used non-invasive technique for concomitant assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the level both of hepatic steatosis and fibrosis as well as the associated risk factors in patients referred to our unit with clinically suspected NAFLD or diagnosed by abdominal ultrasonography. Two hundred four patients were prospectively included in this study and assessed by VCTE with CAP. The final analysis included 181 patients with reliable liver stiffness measurements (LSMs) (53% female, mean age 57.62 ± 11.8 years and BMI 29.48 ± 4.85 kg/m2). According to the cut-off values for steatosis grading, there were 10 (5.5%) patients without steatosis (S0), 30 (16.6%) with mild (S1), 45 (24.9%) moderate (S2), and 96 (53%) severe (S3) steatosis. Based on LSM, there were 73 (40.3%) patients without fibrosis (F0), 42 (23.2%) with mild (F1), 32 (17.7%) significant (F2), 19 (10.5%) advanced (F3) fibrosis, and 15 (8.3%) with cirrhosis (F4). In addition, we found an association between several metabolic components and hepatic steatosis and fibrosis. Thus, in the multivariate analysis, higher BMI, fasting plasma glucose, triglycerides, low-density lipoprotein cholesterol, and serum uric were associated with increased CAP. Furthermore, higher serum uric acid and alpha-fetoprotein together with lower platelets count and albumin levels were associated with increased LSM. The assessment of steatosis and fibrosis using VCTE and CAP should be performed in all patients with suspected or previously diagnosed NAFLD in units with available facilities.


AIDS ◽  
2016 ◽  
Vol 30 (17) ◽  
pp. 2635-2643 ◽  
Author(s):  
Élise Vuille-Lessard ◽  
Bertrand Lebouché ◽  
Lynda Lennox ◽  
Jean-Pierre Routy ◽  
Cecilia T. Costiniuk ◽  
...  

Hepatology ◽  
2017 ◽  
Vol 65 (6) ◽  
pp. 2126-2128 ◽  
Author(s):  
Thomas Karlas ◽  
Sebastian Beer ◽  
Jonas Babel ◽  
Harald Busse ◽  
Alexander Schaudinn ◽  
...  

Author(s):  
Yu-Pei Zhuang ◽  
Yi-Ting Zhang ◽  
Hao-Jie Zhong ◽  
Xing-Xiang He

Objective To investigate the association between intestinal permeability and severity of nonalcoholic fatty liver disease (NAFLD), and the value of intestinal permeability in predicting the efficacy of metabolic therapy for NAFLD. Methods Disease severity was compared between patients with normal and elevated intestinal permeability; correlations between D-lactate and different NAFLD parameters were analyzed; and the effects of metabolic therapy on NAFLD patients with normal and elevated intestinal permeability were evaluated. Results A total of 190 patients with NAFLD were enrolled. NAFLD patients with elevated intestinal permeability had significantly higher levels of liver test parameters, liver ultrasonographic fat attenuation parameter, triglyceride, homeostasis model assessment of insulin resistance value and diamine oxidase (all P˂0.05) than NAFLD patients with normal intestinal permeability. Further, serum D-lactate levels were positively correlated with alanine transaminase, aspartate transaminase, gamma-glutamyl transpeptidase, total bilirubin, indirect bilirubin, fat attenuation parameter, triglyceride, and diamine oxidase (all P˂0.05). Moreover, NAFLD patients with elevated intestinal permeability showed less improvement in TG levels (P=0.014) after metabolic therapy. Conclusion Intestinal permeability correlates with the disease severity in patients with NAFLD. Moreover, intestinal permeability may have value for predicting the efficacy of metabolic therapy for NAFLD patients.


Sign in / Sign up

Export Citation Format

Share Document